Sign up online today & collaborate
or click here to find out more
Endo International is buying privately-held Par Pharmaceuticals for $8.05 billion, in a transformative move that significantly expands its generics presence.
The transaction, which has been approved by both sets of directors and is expected to close in the second half of this year, will see Endo pay around $1.55 billion in equity (18 million shares) and $6.50 billion in cash to Par shareholders.For more click here
Source: Pharma Times